4.7 Meeting Abstract

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/jco.2010.28.15_suppl.3006

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available